We are studying the safety and effectiveness of combining osimertinib with datopotamab deruxtecan in patients with advanced non-small cell lung cancer that has an EGFR mutation. This trial aims to see if the combination works better than osimertinib alone.
Health conditions and diseases that the clinical trial is designed to study and treat.
Non-squamous non-small cell lung cancer (NSCLC) is a type of lung cancer that does not have squamous cell characteristics and can be driven by mutations in the epidermal growth factor receptor (EGFR). This condition can be locally advanced or metastatic, meaning it may spread to other parts of the body.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
